Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients

European Journal of Clinical Pharmacology

Volumn 67, Issue 11, 2011, Pages 1119-1130

  Shrif, Nassr Eldin M A ^a   Won, Hong Hee ^b   Lee, Seung Tae ^a   Park, Jun Hee ^b   Kim, Ka Kyung ^a,b   Kim, Min Ji ^b   Kim, Seonwoo ^b   Lee, Soo Youn ^a   Ki, Chang Seok ^a   Osman, Ihsan M ^c   Rhman, Enaam A ^c   Ali, Ibtisam A ^d   Idris, M N A ^e   Kim, Jong Won ^a  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Radiation and Isotope Centre Khartoum (RICK)   (Sudan)

^d UNIVERSITY OF KHARTOUM   (Sudan)

^e UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

CYP2C9; Single nucleotide polymorphism; Sudanese; VKORC1; Warfarin

Indexed keywords

WARFARIN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; DOSE RESPONSE; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PHARMACOGENETICS; POL3S GENE; PREDICTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; SUDANESE; TREATMENT INDICATION; VKORC1 GENE;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SUDAN; WARFARIN; YOUNG ADULT;

EID: 80054761679     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1060-1     Document Type: Article

References (49)

1. J Hirsh J Dalen DR Anderson L Poller H Bussey J Ansell D Deykin 2001 Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 119 1 Suppl 8S 21S 11157640 10.1378/chest.119.1-suppl.8S 1:CAS:528:DC%2BD3MXhtlamsro%3D (Pubitemid 32154192)
2. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18):3827-3834. doi: 10.1182/blood-2009-12- 255992
3. TP Moyer DJ O'Kane LM Baudhuin CL Wiley A Fortini PK Fisher DM Dupras R Chaudhry P Thapa AR Zinsmeister JA Heit 2009 Warfarin sensitivity genotyping: a review of the literature and summary of patient experience Mayo Clin Proc 84 12 1079 1094 10.4065/mcp.2009.0278 19955245 10.4065/mcp.2009.0278 1:CAS:528:DC%2BC3cXhs1akuw%3D%3D
4. H Takahashi H Echizen 2001 Pharmacogenetics of warfarin elimination and its clinical implications Clin Pharmacokinet 40 8 587 603 11523725 10.2165/00003088-200140080-00003 1:CAS:528:DC%2BD3MXmsl2gsb4%3D (Pubitemid 32758581)
5. AK Hamberg ML Dahl M Barban MG Scordo M Wadelius V Pengo R Padrini EN Jonsson 2007 A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy Clin Pharmacol Ther 81 4 529 538 10.1038/sj.clpt.6100084 17301738 10.1038/sj.clpt.6100084 1:CAS:528:DC%2BD2sXkvFymu7s%3D (Pubitemid 46452304)
6. LS Kaminsky Z-Y Zhang 1997 Human P450 metabolism of warfarin Pharmacol Ther 73 1 67 74 9014207 10.1016/S0163-7258(96)00140-4 1:CAS:528: DyaK28Xns1Cjsrw%3D (Pubitemid 26425815)
7. M Wadelius M Pirmohamed 2007 Pharmacogenetics of warfarin: current status and future challenges Pharmacogenomics J 7 2 99 111 10.1038/sj.tpj.6500417 16983400 10.1038/sj.tpj.6500417 1:CAS:528:DC%2BD2sXjvVaqs7s%3D (Pubitemid 46567142)
8. MW Linder 2001 Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin Clin Chim Acta 308 1-2 9 15 11412812 10.1016/S0009-8981(01)00420-X 1:CAS:528:DC%2BD3MXksVylsrw%3D (Pubitemid 32537605)
9. JD Lindh L Holm ML Andersson A Rane 2009 Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis Eur J Clin Pharmacol 65 4 365 375 19031075 10.1007/s00228-008-0584-5 1:CAS:528: DC%2BD1MXjt1ShsrY%3D
10. S Sanderson J Emery J Higgins 2005 CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis Genet Med 7 2 97 104 15714076 10.1097/01.GIM.0000153664.65759.CF 1:CAS:528:DC%2BD2MXhtl2mtL4%3D (Pubitemid 40261834)
11. J Sistonen S Fuselli JU Palo N Chauhan H Padh A Sajantila 2009 Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales Pharmacogenet Genomics 19 2 170 179 10.1097/FPC. 1090b1013e32831ebb32830 19151603 10.1097/FPC.0b013e32831ebb30 1:CAS:528:DC%2BD1MXmvVartg%3D%3D
12. M Scordo E Aklillu U Yasar M Dahl E Spina M Ingelman-Sundberg 2001 Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population Br J Clin Pharmacol 52 4 447 450 11678789 10.1046/j.0306-5251.2001. 01460.x 1:CAS:528:DC%2BD3MXnvVansLY%3D (Pubitemid 32939447)
13. AC Allabi JL Gala Y Horsmans 2005 CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population Pharmacogenet Genomics 15 11 779 786 16220110 10.1097/01.fpc.0000174787.92861.91 1:CAS:528:DC%2BD2MXhtV2rt7fP (Pubitemid 41531727)
14. J Blaisdell LF Jorge-Nebert S Coulter SS Ferguson SJ Lee B Chanas T Xi H Mohrenweiser B Ghanayem JA Goldstein 2004 Discovery of new potentially defective alleles of human CYP2C9 Pharmacogenetics 14 8 527 537 15284535 10.1097/01.fpc.0000114759.08559.51 1:CAS:528:DC%2BD2cXmtVGgtbs%3D (Pubitemid 39106854)
15. LJ Dickmann AE Rettie MB Kneller RB Kim AJ Wood CM Stein GR Wilkinson UI Schwarz 2001 Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans Mol Pharmacol 60 2 382 387 11455026 1:CAS:528:DC%2BD3MXlsFantrg%3D (Pubitemid 32678304)
16. RS Kidd TB Curry S Gallagher T Edeki J Blaisdell JA Goldstein 2001 Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin Pharmacogenetics 11 9 803 808 11740344 10.1097/00008571-200112000-00008 1:CAS:528:DC%2BD38XnsFKqs74%3D (Pubitemid 33151515)
17. Yang L, Ge W, Yu F, Zhu H (2010) Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res 125(4): e159-e166. doi: 10.1016/j.thromres.2009. 10.017
18. MJ Rieder AP Reiner BF Gage DA Nickerson CS Eby HL McLeod DK Blough KE Thummel DL Veenstra AE Rettie 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 22 2285 2293 10.1056/NEJMoa044503 15930419 10.1056/NEJMoa044503 1:CAS:528: DC%2BD2MXksl2ltrk%3D (Pubitemid 40740552)
19. SC Lee SS Ng J Oldenburg PY Chong S Rost JY Guo HL Yap SC Rankin HB Khor TC Yeo KS Ng R Soong BC Goh 2006 Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population Clin Pharmacol Ther 79 3 197 205 10.1016/j.clpt.2005.11.006 16513444 10.1016/j.clpt.2005.11.006 1:CAS:528:DC%2BD28XitVKhurw%3D
20. NA Limdi TM Beasley MR Crowley JA Goldstein MJ Rieder DA Flockhart DK Arnett RT Acton N Liu 2008 VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Pharmacogenomics 9 10 1445 1458 10.2217/14622416.9.10.1445 18855533 10.2217/14622416.9.10.1445 1:CAS:528:DC%2BD1cXht1Glu7%2FI
21. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA (2010) Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 87(4):459-464. doi: 10.1038/clpt.2009.223
22. H Schelleman Z Chen C Kealey AS Whitehead J Christie M Price CM Brensinger CW Newcomb CF Thorn FF Samaha SE Kimmel 2007 Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians Clin Pharmacol Ther 81 5 742 747 17329985 10.1038/sj.clpt.6100144 1:CAS:528:DC%2BD2sXlsFCqtrg%3D (Pubitemid 46625114)
23. JL Anderson BD Horne SM Stevens AS Grove S Barton ZP Nicholas SFS Kahn HT May KM Samuelson JB Muhlestein JF Carlquist for the Couma-Gen Investigators 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 22 2563 2570 10.1161/circulationaha.107.737312 17989110 10.1161/CIRCULATIONAHA.107.737312 1:CAS:528:DC%2BD2sXhtlagsb3F (Pubitemid 350179221)
24. TE Klein RB Altman N Eriksson BF Gage SE Kimmel MT Lee NA Limdi D Page DM Roden MJ Wagner MD Caldwell JA Johnson 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 8 753 764 19228618 10.1056/NEJMoa0809329
25. EA Millican PA Lenzini PE Milligan L Grosso C Eby E Deych G Grice JC Clohisy RL Barrack RSJ Burnett D Voora S Gatchel A Tiemeier BF Gage 2007 Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood 110 5 1511 1515 10.1182/blood-2007-01-069609 17387222 10.1182/blood-2007-01-069609 1:CAS:528:DC%2BD2sXhtVSgsb3N (Pubitemid 47443966)
26. K Obayashi K Nakamura J Kawana H Ogata K Hanada M Kurabayashi A Hasegawa K Yamamoto R Horiuchi 2006 VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients Clin Pharmacol Ther 80 2 169 178 10.1016/j.clpt.2006.04.010 16890578 10.1016/j.clpt.2006.04.010 1:CAS:528:DC%2BD28XotFKhtrY%3D (Pubitemid 44160690)
27. H Schelleman J Chen Z Chen J Christie CW Newcomb CM Brensinger M Price AS Whitehead C Kealey CF Thorn FF Samaha SE Kimmel 2008 Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans Clin Pharmacol Ther 84 3 332 339 18596683 10.1038/clpt.2008.101 1:CAS:528: DC%2BD1cXhtVShtr7E
28. LS Tham BC Goh A Nafziger JY Guo LZ Wang R Soong SC Lee 2006 A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 Clin Pharmacol Ther 80 4 346 355 10.1016/j.clpt.2006.06.009 17015052 10.1016/j.clpt.2006.06.009 1:CAS:528:DC%2BD28XhtVWqurjM (Pubitemid 44479750)
29. M Yoshizawa H Hayashi Y Tashiro S Sakawa H Moriwaki T Akimoto O Doi M Kimura Y Kawarasaki K Inoue K Itoh 2009 Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients Thromb Res 124 2 161 166 10.1016/j.thromres.2008. 11.011 19135231 10.1016/j.thromres.2008.11.011 1:CAS:528:DC%2BD1MXms1Wht7o%3D
30. Y Zhu M Shennan KK Reynolds NA Johnson MR Herrnberger R Valdes Jr MW Linder 2007 Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes Clin Chem 53 7 1199 1205 10.1373/clinchem.2006. 078139 17510308 10.1373/clinchem.2006.078139 1:CAS:528:DC%2BD2sXntlCqsLc%3D (Pubitemid 47020974)
31. BF Gage C Eby JA Johnson E Deych MJ Rieder PM Ridker PE Milligan G Grice P Lenzini AE Rettie CL Aquilante L Grosso S Marsh T Langaee LE Farnett D Voora DL Veenstra RJ Glynn A Barrett HL McLeod 2008 Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 3 326 331 18305455 10.1038/clpt.2008.10 1:CAS:528:DC%2BD1cXhtVShtr7F
32. LH Cavallari NA Limdi 2009 Warfarin pharmacogenomics Curr Opin Mol Ther 11 3 243 251 19479657 1:CAS:528:DC%2BC3cXnt1Kgu7w%3D
33. SA Tishkoff FA Reed FR Friedlaender C Ehret A Ranciaro A Froment JB Hirbo AA Awomoyi JM Bodo O Doumbo M Ibrahim AT Juma MJ Kotze G Lema JH Moore H Mortensen TB Nyambo SA Omar K Powell GS Pretorius MW Smith MA Thera C Wambebe JL Weber SM Williams 2009 The genetic structure and history of Africans and African Americans Science 324 5930 1035 1044 19407144 10.1126/science.1172257 1:CAS:528:DC%2BD1MXmtVKlsbs%3D
34. SA Tishkoff BC Verrelli 2003 Patterns of human genetic diversity: implications for human evolutionary history and disease Annu Rev Genomics Hum Genet 4 293 340 14527305 10.1146/annurev.genom.4.070802.110226 1:CAS:528:DC%2BD3sXptFWmtbk%3D (Pubitemid 37392927)
35. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE (2010) New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 70(3):393-399
36. SB Gabriel SF Schaffner H Nguyen JM Moore J Roy B Blumenstiel J Higgins M DeFelice A Lochner M Faggart SN Liu-Cordero C Rotimi A Adeyemo R Cooper R Ward ES Lander MJ Daly D Altshuler 2002 The structure of haplotype blocks in the human genome Science 296 5576 2225 2229 10.1126/science.1069424 12029063 10.1126/science.1069424 1:CAS:528:DC%2BD38XkvFGhtrc%3D (Pubitemid 34680308)
37. Y Benjamini Y Hochberg 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc B Methodol 57 1 289 300
38. N Limdi J Goldstein J Blaisdell T Beasley C Rivers R Acton 2007 Influence of CYP2C9 genotype on warfarin dose among African American and European Americans Per Med 4 2 157 169 10.2217/17410541.4.2.157 19802360 10.2217/17410541.4.2.157 1:CAS:528:DC%2BD2sXmslKrur4%3D (Pubitemid 46845895)
39. AM Holbrook JA Pereira R Labiris H McDonald JD Douketis M Crowther PS Wells 2005 Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 10 1095 1106 15911722 10.1001/archinte.165.10.1095 1:CAS:528:DC%2BD2MXlsFaju78%3D (Pubitemid 40720733)
40. JK Pritchard M Stephens P Donnelly 2000 Inference of population structure using multilocus genotype data Genetics 155 2 945 959 10835412 1:STN:280:DC%2BD3cvislKrtA%3D%3D (Pubitemid 30397141)
41. JA Goldstein JA Blaisdell NA Limdi 2009 A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy Blood Cells Mol Dis 42 2 155 158 10.1016/j.bcmd.2008.10.011 19083245 10.1016/j.bcmd.2008.10.011 1:CAS:528:DC%2BD1MXhsFKrt7o%3D
42. AC Allabi JL Gala Y Horsmans MO Babaoglu A Bozkurt M Heusterspreute U Yasar 2004 Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans Clin Pharmacol Ther 76 2 113 118 10.1016/j.clpt.2004.04.001 15289788 10.1016/j.clpt.2004.04.001 1:CAS:528:DC%2BD2cXmt1Ogurg%3D (Pubitemid 39013401)
43. A Matimba J Del-Favero C Van Broeckhoven C Masimirembwa 2009 Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects Hum Genomics 3 2 169 190 19164093 1:CAS:528:DC%2BC3cXpt1yrsro%3D
44. G D'Andrea RL D'Ambrosio P Di Perna M Chetta R Santacroce V Brancaccio E Grandone M Margaglione 2005 A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2 645 649 10.1182/blood-2004-06-2111 15358623 10.1182/blood-2004-06- 2111 (Pubitemid 40070748)
45. JM John DM Herrington 2006 Maintenance warfarin dose varies according to two haplotypes of the vitamin K epoxide reductase gene Future Cardiol 2 1 29 32 10.2217/14796678.2.1.29 19804128 10.2217/14796678.2.1.29 1:CAS:528: DC%2BD28XosVSgtQ%3D%3D
46. N Al-Zahery O Semino G Benuzzi C Magri G Passarino A Torroni AS Santachiara-Benerecetti 2003 Y-chromosome and mtDNA polymorphisms in Iraq, a crossroad of the early human dispersal and of post-Neolithic migrations Mol Phylogenet Evol 28 3 458 472 12927131 10.1016/S1055-7903(03)00039-3 1:CAS:528:DC%2BD3sXmt1egsbs%3D (Pubitemid 37436115)
47. HY Hassan PA Underhill LL Cavalli-Sforza ME Ibrahim 2008 Y-chromosome variation among Sudanese: restricted gene flow, concordance with language, geography, and history Am J Phys Anthropol 137 3 316 323 18618658 10.1002/ajpa.20876
48. S Cal JR Peinado M Llamazares V Quesada A Moncada-Pazos C Garabaya C Lopez-Otin 2006 Identification and characterization of human polyserase-3, a novel protein with tandem serine-protease domains in the same polypeptide chain BMC Biochem 7 9 16566820 10.1186/1471-2091-7-9
49. F Takeuchi R McGinnis S Bourgeois C Barnes N Eriksson N Soranzo P Whittaker V Ranganath V Kumanduri W McLaren L Holm J Lindh A Rane M Wadelius P Deloukas 2009 A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLoS Genet 5 3 e1000433 10.1371/journal.pgen.1000433 19300499 10.1371/journal.pgen.1000433